Activity Date: 04/20/2021
Access to buprenorphine continues to be problematic for many patients potentially due to stigma from patients, the healthcare system, and the community. During this session, we will explore what barriers others have encountered and how they have dealt with it. We will also explore the stigmas surrounding buprenorphine and brainstorm ideas for how to combat this problem. Though the recent HHS guidelines for enhanced buprenorphine access were not implemented, we will discuss how the culture of opioid prescribing and opioid use disorder treatment are changing.
David Dadiomov, PharmD, BCPP
Mika Michaels, PharmD, BCPP
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
